BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics Corp., a biotech firm specializing in cancer immunotherapies, has announced an $8.5 million offering of common shares or pre-funded warrants at a price of $0.69 each, under the Nasdaq rules. The proceeds are intended for working capital, general corporate purposes, and advancing the company’s business objectives.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
